Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic ...
Learn more about whether Bausch + Lomb Corporation or Omnicell, Inc. is a better investment based on AAII's A+ Investor ...
The company recently invested an additional €90m to expand its capabilities at its contact lens manufacturing plant in ...
Papa took over as the new CEO of Bausch & Lomb, and oversaw the $2.5bn acquisition of the dry eye disease therapy XIIDRA and other ophthalmology assets from Swiss Pharma giant Novartis AG (NVS ...
Meet the new Valeant: Drugmaker drops tainted name to become Bausch Health in July rebrand A buyout would be one of the largest private equity healthcare deals of the year as Bausch + Lomb has an ...
Bausch + Lomb has a fifty-two week low of $13.16 and a fifty-two week high of $21.69 ... and contact lens care products ...
Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic competition in ...
Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global leader in eye health products with a market capitalization of $6.55 billion, has been navigating a complex market landscape in 2024.
Elios Vision former chairman and CEO Elliot Friedman said: “Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help ...
HighTower Advisors LLC raised its stake in shares of Bausch + Lomb Co. (NYSE:BLCO – Free Report) by 14.7% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 24,661 shares of the ...